Key Takeaway: AbbVie has announced its acquisition of Apogee for $135.11 per share, totaling around $10.9 billion. This acquisition aims to enhance AbbVie's immunology portfolio and expand its reach to more patients globally. Additionally, Apogee reported positive results from its 16-week Phase 2 APEX Part B trial, supporting further pipeline advancements.
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie is acquiring Apogee, indicating strong market confidence.
The acquisition values Apogee at approximately $10.9 billion.
Positive Phase 2 results support further development of the pipeline.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+138%
120-day peak, hindsight
Typical move
1.8%
average across 3 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
APG777
Phase 2 · Atopic Dermatitis
Full Press Release Details
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of
Frequently Asked Questions
What is the acquisition price for Apogee?
AbbVie is acquiring Apogee for $135.11 per share.
What is the total equity value of the acquisition?
The total equity value of the acquisition is approximately $10.9 billion.
What positive results did Apogee report?
Apogee reported positive 16-week Phase 2 APEX Part B results.
How will the acquisition benefit AbbVie?
The acquisition will enhance AbbVie's differentiated immunology portfolio.